“…In tumors, the expression and function of integrins are abnormal, which promotes tumor development, angiogenesis, invasion, metastasis, and immune escape and causes tumor tolerance to radiotherapy and chemotherapy [11][12][13]. The integrin α6 subunit is CD49f, which can form α6β1 or α6β4 integrins with the integrin β1 subunit (CD29) and integrin β4 subunit (CD104), and the ligand of α6β1 and α6β4 is laminin [14][15][16][17][18][19]. Integrin α6 is significantly overexpressed in a variety of cancers, including hepatocellular carcinoma (HCC), pancreatic cancer, colorectal adenocarcinoma, head and neck squamous cell carcinoma, acute myeloid leukemia, breast cancer, lung squamous cell carcinoma, esophageal squamous cell carcinoma, and other cancers, and abnormally high expression has been associated with lower survival rates and poorer prognosis [20][21][22].…”